Literature DB >> 28391631

Estimates of heritability of atrial fibrillation in the Standardbred racehorse.

M Kraus1, P W Physick-Sheard2, L F Brito1, F S Schenkel1.   

Abstract

BACKGROUND: The number of Standardbred racehorses admitted to the Ontario Veterinary College Teaching Hospital (Guelph, Canada) for treatment of atrial fibrillation (AF) has been on the rise since the early 1990s. A small number of sires have been contributing to a large proportion of cases, indicating there may be a genetic predisposition to the arrhythmia in this breed.
OBJECTIVES: The objectives of this study were to determine the heritability of AF in Standardbred horses and whether heritability of the arrhythmia differs across gaits and/or sexes. STUDY
DESIGN: Heritability study based on retrospective review of clinical records and publicly available pedigree and racing records.
METHODS: Standardbred horses admitted to hospital for treatment of AF that were born between 1978 and 2007 comprised the affected case population (n = 204). Five randomly selected racing contemporaries for each case, assumed to not suffer from the arrhythmia, comprised the control population (n = 1017). Racing contemporaries were identified by examining the race records of affected horses within the 6 months prior to their admission, and randomly selecting sex- and gait-matched horses from these races. Heritability was estimated from the sampled horses as a whole (n = 1221), as well as for both sexes and gaits, using a generalised linear mixed model.
RESULTS: Heritability of AF on the underlying liability scale was estimated to be (±s.e.) 0.30±0.04 in the entire data set; 0.30±0.06 in males; 0.24±0.08 in females; and 0.32±0.05 in pacers. After conversion to the observed scale, heritability estimates were 0.14, 0.15, 0.09 and 0.15, respectively. MAIN LIMITATIONS: There were insufficient data to estimate heritability of AF for trotters.
CONCLUSIONS: Modest heritability estimates were found for AF in the Standardbred horse, particularly in males and pacers, which support the hypothesis that there is a genetic contribution to the arrhythmia in this breed. The Summary is available in Chinese - See Supporting Information.
© 2017 EVJ Ltd.

Entities:  

Keywords:  cardiac arrhythmia; equine diseases; genetic parameters; horse

Mesh:

Year:  2017        PMID: 28391631     DOI: 10.1111/evj.12687

Source DB:  PubMed          Journal:  Equine Vet J        ISSN: 0425-1644            Impact factor:   2.888


  6 in total

Review 1.  Retrospective review of atrial fibrillation in Standardbred racehorses at a tertiary care facility in Atlantic Canada.

Authors:  Jennifer J Burns; Kathleen M MacMillan; Emily E John
Journal:  Can Vet J       Date:  2022-10       Impact factor: 1.075

2.  Incidence, recurrence, and outcome of postrace atrial fibrillation in Thoroughbred horses.

Authors:  Laura C Nath; Adrian D Elliott; Joe Weir; Peter Curl; Sarah M Rosanowski; Samantha Franklin
Journal:  J Vet Intern Med       Date:  2021-02-19       Impact factor: 3.333

3.  Analysis of Genetic Diversity in the American Standardbred Horse Utilizing Short Tandem Repeats and Single Nucleotide Polymorphisms.

Authors:  Elizabeth Esdaile; Felipe Avila; Rebecca R Bellone
Journal:  J Hered       Date:  2022-07-09       Impact factor: 2.679

Review 4.  Ten years of the horse reference genome: insights into equine biology, domestication and population dynamics in the post-genome era.

Authors:  T Raudsepp; C J Finno; R R Bellone; J L Petersen
Journal:  Anim Genet       Date:  2019-09-30       Impact factor: 3.169

5.  Marginal ancestral contributions to atrial fibrillation in the Standardbred racehorse: Comparison of cases and controls.

Authors:  Megan Kraus; Peter Physick-Sheard; Luiz F Brito; Mehdi Sargolzaei; Flávio S Schenkel
Journal:  PLoS One       Date:  2018-05-15       Impact factor: 3.240

Review 6.  Paroxysmal Atrial Fibrillation in Horses: Pathophysiology, Diagnostics and Clinical Aspects.

Authors:  Sofie Troest Kjeldsen; Sarah Dalgas Nissen; Rikke Buhl; Charlotte Hopster-Iversen
Journal:  Animals (Basel)       Date:  2022-03-10       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.